MELBOURNE, Australia and INDIANAPOLIS, Oct. 21, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a financial update on its commercial and operational performance for the quarter ended September 30, 2026 (Q3 2026).Q3 2026 Highlights[1] Group revenue of US$245 million increased 19% over the prior corresponding quarter (Q3 2025) driven by continued strong demand for the commercial portfolio, in line with expectations. September sales drove a higher quarterly exit rate indicating continued strength in underlying demand for Telix’s PSMA products. Precision Medicine revenue of US$201 million, increased 30% over the prior corresponding quarter, driven by both Gozellix®…
News Timeline:
Track the development of this news story across the Internet.